News >

Update Confirms Benefit of Encorafenib/Binimetinib Combo in Melanoma

Jason M. Broderick @jasoncology
Published: Thursday, May 11, 2017

Keith Flaherty, MD

Keith Flaherty, MD

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of disease progression or death by 23% compared with single-agent encorafenib for patients with BRAF-mutant melanoma, according to findings from part 2 of the phase III COLUMBUS trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication